- Page 1 and 2: Genetic susceptibility to adverse d
- Page 3 and 4: The work presented in this thesis w
- Page 5: Promotiecommissie Promotoren: Prof.
- Page 12 and 13: General Introduction 1 General Intr
- Page 14 and 15: General Introduction cells where it
- Page 16: General Introduction 27. 28. 29. 30
- Page 20 and 21: 2 Age- and gender specific incidenc
- Page 22 and 23: Age- and gender specific incidence
- Page 24 and 25: Age- and gender specific incidence
- Page 26 and 27: Age- and gender specific incidence
- Page 28: Age- and gender specific incidence
- Page 32 and 33: 3.1 Common ABCB1 variants are assoc
- Page 34 and 35: Common ABCB1 variants are associate
- Page 36 and 37: Common ABCB1 variants are associate
- Page 38 and 39: Common ABCB1 variants are associate
- Page 40 and 41: Common ABCB1 variants are associate
- Page 42 and 43: Common ABCB1 variants are associate
- Page 44: Common ABCB1 variants are associate
- Page 47 and 48: Chapter 3.2 Introduction Digoxin is
- Page 49 and 50: Chapter 3.2 excluded. Up to 4 QTc m
- Page 51 and 52: Chapter 3.2 Table 1 baseline charac
- Page 53 and 54: Chapter 3.2 Table 3 QTc difference
- Page 55 and 56: Chapter 3.2 Discussion In the prese
- Page 57 and 58:
Chapter 3.2 References 1. 2. 3. 4.
- Page 60 and 61:
3.3 ABCB1 (MDR1) gene polymorphisms
- Page 62 and 63:
ABCB1 (MDR1) gene polymorphisms are
- Page 64 and 65:
ABCB1 (MDR1) gene polymorphisms are
- Page 66 and 67:
ABCB1 (MDR1) gene polymorphisms are
- Page 68 and 69:
ABCB1 (MDR1) gene polymorphisms are
- Page 70 and 71:
ABCB1 (MDR1) gene polymorphisms are
- Page 72:
ABCB1 (MDR1) gene polymorphisms are
- Page 76 and 77:
4.1 Common NOS1AP variants are asso
- Page 78 and 79:
Common NOS1AP variants are associat
- Page 80 and 81:
Common NOS1AP variants are associat
- Page 82 and 83:
Common NOS1AP variants are associat
- Page 84 and 85:
Common NOS1AP variants are associat
- Page 86 and 87:
Common NOS1AP variants are associat
- Page 88:
Common NOS1AP variants are associat
- Page 91 and 92:
Chapter 4.2 Introduction Digoxin (d
- Page 93 and 94:
Chapter 4.2 Genotyping. All partici
- Page 95 and 96:
Chapter 4.2 Table 1 Baseline charac
- Page 97 and 98:
Chapter 4.2 Table 2 NOS1AP genotype
- Page 99 and 100:
Chapter 4.2 of digoxin users we fou
- Page 101 and 102:
Chapter 4.2 References 1. 2. 3. 4.
- Page 104 and 105:
4.3 Cardiovascular drugs, NOS1AP an
- Page 106 and 107:
Cardiovascular drugs, NOS1AP and QT
- Page 108 and 109:
Cardiovascular drugs, NOS1AP and QT
- Page 110 and 111:
Cardiovascular drugs, NOS1AP and QT
- Page 112 and 113:
Cardiovascular drugs, NOS1AP and QT
- Page 114 and 115:
Cardiovascular drugs, NOS1AP and QT
- Page 116 and 117:
Cardiovascular drugs, NOS1AP and QT
- Page 118:
Cardiovascular drugs, NOS1AP and QT
- Page 121 and 122:
Chapter 4.4 Introduction Sulfonylur
- Page 123 and 124:
Chapter 4.4 potentially affecting t
- Page 125 and 126:
Chapter 4.4 Table 2 Average change
- Page 127 and 128:
Chapter 4.4 had lower mortality rat
- Page 129 and 130:
Chapter 4.4 In population based stu
- Page 131 and 132:
Chapter 4.4 26. 27. 28. 29. 30. 31.
- Page 134:
5 Effect of ABCB1 and NOS1AP genoty
- Page 137 and 138:
Chapter 5 Introduction Digoxin is o
- Page 139 and 140:
Chapter 5 Echocardiography. Our pri
- Page 141 and 142:
Chapter 5 Table 1 Population charac
- Page 143 and 144:
Chapter 5 Table 3 Association betwe
- Page 145 and 146:
Chapter 5 Table 5 Effect of digoxin
- Page 147 and 148:
Chapter 5 Discussion Digoxin is kno
- Page 149 and 150:
Chapter 5 References 1. 2. 3. 4. 5.
- Page 152:
6 General discussion
- Page 155 and 156:
Chapter 6 2 per 1000 person years o
- Page 157 and 158:
Chapter 6 cardial repolarization. B
- Page 159 and 160:
Chapter 6 ated with reduced mortali
- Page 161 and 162:
Chapter 6 selection bias. However,
- Page 163 and 164:
Chapter 6 of the main problems is t
- Page 165 and 166:
Chapter 6 References 1. 2. 3. 4. 5.
- Page 167 and 168:
Chapter 6 49. 50. 51. 52. 53. 54. 5
- Page 169 and 170:
Chapter 6 2007;356(11):1094-7. 101.
- Page 172:
7 Summary 171
- Page 175 and 176:
Chapter 7.1 2677-3435 TTT-haplotype
- Page 178 and 179:
Samenvatting 7.2 Samenvatting Ondan
- Page 180:
Samenvatting gereerden de regressie
- Page 183 and 184:
Chapter 8 proefschrift. Verder spec
- Page 186:
9 About the author Albert-Jan Aarno
- Page 189 and 190:
Chapter 10 Aarnoudse ALHJ, Dieleman